ArticleScientific reports2025
Network pharmacology and experimental validation to elucidate the pharmacological mechanisms of Guben Xiezhuo decoction against renal fibrosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Targeting the fibrosis-inflammation-oxidative stress axis: multifaceted mechanisms of salidroside in chronic organ fibrosis.Apoptosis : an international journal on programmed cell death · 2026Review
- Systems pharmacology of traditional Chinese medicine in fibrosis: From multi-target mechanisms to translational validation.Chinese herbal medicines · 2026Review
- Molecular dynamics simulation in traditional Chinese medicine research: from molecular mechanisms to multiscale validation.Frontiers in chemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Guben Xiezhuo decoction (GBXZD), a traditional Chinese medicine (TCM), shows promise in treating chronic kidney disease (CKD) by reducing renal fibrosis (RF). This study seeks to uncover the exact mechanism behind GBXZD's therapeutic effects. This study identified 14 active components and 18 specific metabolites in the serum of GBXZD-treated rats via mass spectrometry. Potential target proteins were predicted using PubChem, TCMSP, and SwissTargetPrediction databases and refined through OMIM and Genecards databases. A total of 276 proteins were filtered from these potential target proteins to develop a protein-protein interaction (PPI) network to explore the interactions between GBXZD and RF target proteins, revealing significant correlations for proteins such as SRC, EGFR, and MAPK3. Subsequently, the active components and specific metabolites were employed for molecule docking simulation to assess their interactions with EGFR protein. The effects and mechanisms of GBXZD on RF were validated in a unilateral ureteral obstruction (UUO) rat model by assessing changes in RF-related protein expressions identified from the PPI network. GBXZD showed a reduction in the phosphorylation expression of SRC, EGFR, ERK1, JNK, and STAT3. In vitro, LPS stimulated HK 2 cells treated with the identified GBXZD bioactive components trans-3-Indoleacrylic acid and Cuminaldehyde exhibited significantly enhanced viability and reduced fibrotic marker expression and p-EGFR levels. KEGG pathway analysis suggested that GBXZD's anti-fibrotic effects might be mediated by inhibiting the EGFR tyrosine kinase inhibitor resistance and MAPK signaling pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.